ClinicalTrials.gg
Active, not recruitingNCT06476158SPecTUpdated Nov 16, 2026

Safer Personalised Cancer Treatment Digital Follow-up

An interventional study of Kaiku Health in Patient Reported Outcome Measure, sponsored by Nordlandssykehuset HF. Active, not recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Nordlandssykehuset HF · Not applicable, Interventional, and Health services research

How we know

Updated Nov 16, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
900
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to investigate patient harm/ adverse events, overall survival and health related quality of life under treatment with immunotherapy medication in cancer patients when they are followed up by a personalized digital program where the patients report symptoms directly to health care personnel.

The main questions the clinical trial aims to answer are:

  • How often and how severe are immunotherapy related adverse events/ side effects when patients are followed up by a digital personalized patient-reporting system compared to standard follow-up?
  • How are life quality and survival affected for patients followed up by a digital personalized patient-reporting system compared to follow-up standard follow-up??

Participants under immunotherapy cancer treatment will be followed up by a digital patient reporting program in one group, and compared to a group of cancer patients receiving the same treatment, but with standard follow-up without a digital program in another group. Researchers will compare the two groups to see if there any differences in how many patients who develop immunotherapy related patient harm and how long the patients live.

Read the detailed description

Cancer patients experience more frequently patient harm than other patients, mostly from systemic anticancer treatment. To reduce avoidable patient harm from modern cancer treatment such as immunotherapy and targeted therapies, precise and clinically relevant measurements are needed.

The study aims through three different sub-studies/ work pacages (WP) to develop electronic methods for measuring automatically injuries in cancer patients, and investigate if electronic patient follow-up (ePRO) can prevent injuries, affect quality of life and survival in patients receiving immunotherapy cancer treatment.

Research has shown that the recommended method for measuring patient harm and medication related adverse events is not specific or sensitive enough to detect cancer-related patient harm. In recent years, three patient harm measurement tools for cancer have been validated based on a manual retrospective review of the patient record. Based on existing technology and research, in WP1 the aim is to develop and validate a fully automatic patient harm measurement tool for retrospective detection of harm in cancer patients receiving immunotherapy. The development of the technological solution is done by Datavarehuset Helse Nord and SAS Institute in an already existing solution (Nordic Clinical Analytics Framework - NCAF) which is used daily in all health trusts in Helse Nord, Northern Norway.

In order to prevent avoidable patient harm and adverse events, it is important to involve the patient in their own treatment. Research on follow-up with ePRO revealed more side effects, increased quality of life and overall survival in cancer patients.

In WP2, the technology developed in WP1 is used to prospectively examine whether follow-up with ePRO compared to standard follow-up results in less adverse events. In WP3, quality of life and survival are investigated with ePRO follow-up compared to standard follow-up. WP1 is a retrospective diagnostic study. WP2 and 3 are clinical cohort studies where a prospective intervention group of cancer patients are followed with ePRO during immunotherapy treatment and compared with a retrospective group of cancer patients followed with standard clinical follow-up. WP2 investigates rates, severity and types of immunotherapy related adverse events in patients monitored with ePRO compared to standard follow-up. WP3 investigates quality of life in the ePRO cohort, and overall survival in patients monitored to standard follow-up.

When the study is completed in 2027, the intention is to have developed and validated an automatic measurement tool for the detection of cancer-related injuries for general use nationally and internationally, and new knowledge about how and if digital follow-up with ePRO can affect patient harm and adverse events, quality of life and survival.

The study contributes to new knowledge about measurement of patient injuries and digital follow-up of cancer patients during active treatment with immunotherapy as a new standard of care in our region.

Adverse events are an additional burden for seriously ill cancer patients. By measuring adverse events that occur in cancer patients, we recognize that these events happen and is a part of oncology that need to be taken to account for each individual patient. Knowledge of the occurrence of adverse events in each individual department will be able to say something about status in each department, so measures can be taken at a system level to improve patient safety and the quality of the health service.

The use of personalized ePRO gives the patient the opportunity to participate actively in the course of their illness, regardless of where and who the patient is. Increased involvement of the patient inthe patient journey has shown to provide increased empowerment, safety, better quality of life and possible increase survival in other studies. Follow-up with ePRO makes it easier for healthcare personnel to detect early signs of potential injuries so that measures can be initiated faster to mitigate potential harm.

02

Conditions studied

  • Patient Reported Outcome Measure

Keywords

  • Adverse events
  • Patient reported outcome
  • Digital follow-up
  • Immunotherapy
  • Routine cancer care
03

In context

Lead sponsor

Nordlandssykehuset HF is the lead sponsor of 21 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Above 18 years of age
  • Cancer diagnosis as primary or secondary diagnosis according to the ICD-10 classification
  • Receiving immunotherapy as systemic anticancer treatment reported with ATC codes for medications.

Exclusion criteria

Exclusion Criteria:

  • Hematological cancer
  • Gynecological cancer
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Active comparator
    Digital follow-up with e-PROs

    Device: Kaiku Health

  • No intervention
    Standard clinical follow-up

Interventions

  • DeviceKaiku Health

    Digital follow-up with Kaiku Health as medical device

06

What researchers measure

Primary outcomes

  1. Incidence and severity of immunotherapy related adverse events (irAEs)

    Incidence of irAEs per 100 patients and per patient, and severity of irAEs graded by Common Terminology Critera for Adverse Events (CTCAE) 0-5 where 0 is no harm, and 5 is death. Consequence of the irAEs are graded by National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP) Index category E-I where E is an error contributing to or resulted in temporary harm and required intervention. I is the maximum value, where an error occurred that may have contributed to or resulted in a patient death.

    Time frame: 3 years

Secondary outcomes

  1. Overall survival

    Implement personalised ePRO immunotherapy follow-up and investigate overall survival compared to standard of care from cancer diagnosis to death, and from start of immunotherapy treatment and intervention to death in the two comparing groups.

    Time frame: 3 years

  2. Health related quality of life

    Implement personalised ePRO immunotherapy follow-up and investigate QoL in intervention group by EORTC QLQ-C30 version 3.0 including global health status, functional scales (physical, role, emotional, cognitive, social) and symptom scales at baseline ( at start cancer treatment), 3, 6 and 12 months under cancer treatment. All of the scales and single-item measures range in score from 0 to 100. A high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL but a high score for a symptom scale represents a high level of symptomatology / problems. Firstly an estimate of the average of the items that contribute to the scale; this is the raw score. Then a linear transformation is used to standardise the raw score, so that scores range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.

    Time frame: 3 years

07

Study locations

1 site
08

References and documents

Publications

  • Aanes SG, Nieder C, Bates DW, Wiig S, Haukland EC. Consequences of adverse events in cancer immunotherapy combinations - a comprehensive real-world analysis. Immunotherapy. 2025 Nov;17(16):1177-1187. doi: 10.1080/1750743X.2025.2600847. Epub 2025 Dec 10. PubMed 41367243 ↗

Individual participant data

Plan to share: Yes — All data are stored for 10 years after the research has concluded, in accordance with the Health Research Act. Identifiable data are destroyed after 10 years. Anonymized quantitative result data are further preserved, stored on a secure server at SIKT, the service provider for the knowledge sector, sikt.no, following their advice on anonymization. Anonymized quantitative result data are further preserved, stored on a secure server at SIKT, the service provider for the knowledge sector, sikt.no, following their advice on anonymization. This will make them searchable and accessible for secondary use in research, educational purposes and for replication and validation

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: 2024 - 2034

Access criteria: Open access

Data sharing details ↗ · app.cristin.no

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jun 2024 to primary completion in Dec 2025, 18 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2025 → Dec 2025 and completion Dec 2027 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2024
First posted
Jun 26, 2024
StartActual
Jun 1, 2024
Primary completionActual
Dec 30, 2025was Jun 2025
CompletionEst.
Dec 30, 2026was Dec 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 16, 2026
Primary completion
Jun 1, 2025→Dec 30, 2025 (actual)
Nov 16, 2026
Study completion
Dec 31, 2027→Dec 30, 2026
Nov 16, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41367243 ↗
Nov 16, 2026
Sponsor
Collaborators added: Helgeland Hospital Trust; collaborators removed: Helgelandssykehuset HF
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Active, not recruiting
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41367243 ↗
    Primary completion Jun 1, 2025→Dec 30, 2025 (now actual)
    Study completion Dec 31, 2027→Dec 30, 2026
    Sponsor Collaborators added: Helgeland Hospital Trust; collaborators removed: Helgelandssykehuset HF
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06476158
Lead sponsor
Nordlandssykehuset HF
Collaborators
University of Tromso, Helgeland Hospital Trust, University Hospital of North Norway
Responsible party
Sponsor
First posted
Jun 26, 2024
Start date
Jun 1, 2024
Primary completion
Dec 30, 2025
Completion
Dec 30, 2026 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion